Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20096430 | 1.00 | HDAC11 (0.53) | HDAC11HDAC6KIF11ADORA2ASCN9A | |
| SCHEMBL20096428 | 0.97 | HDAC11 (0.51) | HDAC11HDAC6KIF11ADORA2ASCN9A | |
| SCHEMBL20096655 | 0.93 | KIF11 (0.46) | HDAC11KIF11ADORA2ASCN9AIRAK4 | |
| SCHEMBL20132833 | 0.89 | KIF11 (0.46) | HDAC11KIF11ADORA2ASCN9AIRAK4 | |
| SCHEMBL20096698 | 0.89 | KIF11 (0.46) | HDAC11KIF11ADORA2ASCN9AIRAK4 | |
| SCHEMBL20096579 | 0.88 | HDAC11 (0.67) | HDAC11HDAC6SCN9A | |
| SCHEMBL29624663 | 0.88 | HDAC11 (0.67) | HDAC11HDAC6SCN9A | |
| SCHEMBL20096633 | 0.87 | HDAC11 (0.50) | HDAC11HDAC6KIF11ADORA2ASCN9A | |
| SCHEMBL29624720 | 0.87 | HDAC11 (0.50) | HDAC11HDAC6KIF11ADORA2ASCN9A | |
| SCHEMBL29624677 | 0.85 | HDAC11 (0.66) | HDAC11HDAC6KIF11IRAK4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2022-07-28 | — | — | US | disclosed |
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885KIF11 269/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885KIF11 269/4885 |
| US-20220235018-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | HDAC11 1/4885HDAC6 6/4885KIF11 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.